Sublingual Ketamine as Breakthrough Analgesia in Patients with Advanced Cancer -- A Feasibility Study

Chris O'brien Lifehouse0 个研究点目标入组 29 人开始时间: 2021年3月23日最近更新: 2023年10月9日

适应症

试验速览

暂无简介。

•1.Adult patients with diagnosis of advanced cancer
•2.Weight >40 kg, and BMI between 18-40 kg•m-2
•3.Moderate to severe pain associated with the cancer diagnosis requiring ongoing opioid analgesia at >60 mg of OMEDD (oral morphine equivalent daily dose)
•4.Self-reporting sub-optimal pain control with current analgesia
•5.Willingness to provide informed consent and willingness to participate and comply with the study requirements.

•1.Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
•2.Participants who are receiving ketamine medication through any route of administration as part their treatment regimen.
•3.Participants with a history of raised intra-cranial pressure, epilepsy, raised intra-ocular pressure, severe cardiac failure, or uncontrolled hypertension
•4.Participants with a history of cognitive impairment which may interfere with their ability to understand the study requirements.
•5.Participants with DSM-V diagnosis of psychotic disorders or dissociative disorders which may resemble the adverse effect of the study medication
•6.The requirement of analgesia is expected to decrease following recruitment into the study.
•7.Participants with life expectancy of less than six weeks

发起方